Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Label, Two-step, Phase Ia/Ib Study of Tumor Targeted Prodrug RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors

NCT04261413 is registered in ClinicalTrials.gov with RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. as lead sponsor.

NCT NCT04261413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04261413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Label, Two-step, Phase Ia/Ib Study of Tumor Targeted Prodrug RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
Lead sponsor
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
Phase
Phase 1
Overall status
Completed
Start date
December 13, 2021
Completion date
March 4, 2026
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors